Bausch Health is a diversified specialty pharmaceutical company with products spanning gastroenterology, dermatology, neurology and other therapeutic areas, as well as consumer health brands. It markets prescription and over-the-counter treatments to physicians, patients and retail channels primarily in North America and other developed markets. The company is the successor to Valeant Pharmaceuticals and retains a broad portfolio of established specialty drugs alongside newer pipeline assets.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 2,530 | — | 148 | — |
| Q3 2025 | 2,681 | — | 179 | — |
| Q4 2025 | 2,796 | — | -112 | — |
| Q1 2026 | 2,524 | — | -1,423 | — |
| Q2 2026 | 2,852 | 12.7% | 258 | 74.3% |
All markets — KeepWinning global stock screener
Other companies on Toronto (TSX): Snowline Gold Corp. (SGD), Southern Cross Gold Consolidated Ltd. (SXGC), Boardwalk Real Estate Investment Trust (BEI UN), Aecon Group Inc. (ARE), Primaris Real Estate Investment Trust (PMZ UN), Extendicare Inc. (EXE)